CGTX — Cognition Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $27.63m
- $2.62m
Annual cashflow statement for Cognition Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.84 | -11.7 | -21.4 | -25.8 | -34 |
| Depreciation | |||||
| Non-Cash Items | 1.24 | 5.15 | 3.57 | 4.67 | 3.94 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.07 | 2.84 | -0.943 | 4.85 | 1.29 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.43 | -3.63 | -18.5 | -16 | -28.5 |
| Capital Expenditures | -0.01 | -0.027 | -0.171 | -0.147 | -0.004 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.01 | -0.027 | -0.171 | -0.147 | -0.004 |
| Financing Cash Flow Items | -0.093 | 8.94 | 0 | — | -0.128 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.76 | 53.2 | 5.55 | 4.52 | 23.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.3 | 49.5 | -13.2 | -11.6 | -4.91 |